Craft
Ogeda

Ogeda

Ogeda Summary

Company summary

Overview
Ogeda is a clinical-stage drug discovery company that invents and develops small molecule drugs targeting G-Protein Coupled Receptors. Ogeda leads the development of NK3 antagonists for the treatment of hormone-dependent pathologies in Women's Health. Its lead product, fezolinetant has shown positive results in a Phase IIa proof-of-concept clinical study in Menopausal Hot Flashes, and studies in PolyCystic Ovary Syndrome and Uterine Fibroids are in progress. Ogeda's portfolio further includes several pre-clinical drug discovery programs in endocrine, CNS and/or inflammatory disorders. Ogeda was acquired by Astellas Pharma on April 2, 2017
Type
Subsidiary
Status
Active
Founded
1994
HQ
Anderlecht, BE | view all locations
Website
https://www.ogeda.com/
Cybersecurity rating
Sectors

Key people

  • Rui Patrao, General Manager

    • Graeme Fraser, Chief Scientific Officer

      • Hamid Hoveyda, Director, Medicinal Chemistry & CMC

        • Vincent Lannoy, Director, Intellectual Property & Legal

          LocationsView all

          1 location detected

          • Anderlecht, Brussels Hoofdstedelijk Gewest HQ

            Belgium

            Marie Curiesquare 50/building 5

          Footer menu